Corcept Therapeutics Inc (CORT)

Industry Biotechnology

This stock can be held in an Investment ISA and an Investment Account

Sell

$81.33

Buy

$89.50

arrow-up$0.86 (+0.99%)

Prices updated at 13 Dec 2025, 00:55 EST

Prices minimum 15 mins delay

Prices in USD

Corcept Therapeutics Inc is engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, psychiatric and oncologic disorders by modulating the effects of cortisol.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Biotechnology

Chairman

Mr. James N. Wilson

CEO

Dr. Joseph K. Belanoff, M.D.

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

500

Head office

101 Redwood Shores Parkway

Redwood City

United States

94065

+1 650 327-3270

ir@corcept.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Mr. David L. Mahoney Independent Director	0.08m
Mr. Daniel N. Swisher,Jr Independent Director	0.06m
Mr. George Leonard Baker, Jr Independent Director	0.07m
Dr. Gregg H. Alton, J.D. Independent Director	0.09m
Dr. Joseph K. Belanoff, M.D. Director, President and Chief Executive Officer	1.14m
Mr. James N. Wilson Chairman of the Board	0.13m
Mr. G. Charles Robb Chief Business Officer and Secretary	0.69m
Mr. Atabak Mokari Chief Financial Officer and Treasurer	0.55m
Mr. Sean Maduck President, Corcept Endocrinology	0.63m
Ms. Kimberly Park Independent Director	0.06m
Mr. Joseph Douglas Lyon Chief Accounting Officer and Chief Technology Officer	-
Dr. Hazel Hunt, PhD Chief Scientific Officer	-
Mr. Joshua M. Murray Independent Director	0.06m
Dr. William Guyer, Pharm.D. Chief Development Officer	0.66m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	12,047,830
Vanguard Group Inc	9,680,592
BlackRock Fund Advisors	8,466,235
Ingalls & Snyder LLC	7,697,984
Renaissance Technologies Corp	6,089,347

Director dealings

Date chevron-l-regular chevron-r-regular	Action
06 Jul 2022	-
31 Jul 2024	-
31 Jul 2024	-
06 Jul 2022	-
27 Dec 2024	-
10 Dec 2024	-
10 Dec 2024	-
10 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-
02 Dec 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.